Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease

Gorm B Jensen; Jørgen Hilden; Bodil Als-Nielsen; Morten Damgaard; Jørgen Fischer Hansen; Stig Hansen; Olav H Helø; Per Hildebrandt; Jens Kastrup; Hans Jørn Kolmos; Erik Kjøller; Inga Lind; Henrik Nielsen; Lars Petersen; Christian M Jespersen; Christian Gluud; CLARICOR Trial Group; Gorm B Jensen; Jørgen Hilden; Bodil Als-Nielsen; Morten Damgaard; Jørgen Fischer Hansen; Stig Hansen; Olav  Holger Helø; Per Hildebrandt; Jens Kastrup; Hans Jørn Kolmos; Erik Kjøller; Inga Lind; Henrik Nielsen; Lars Petersen; Christian Jespersen; Christian Gluud; CLARICOR Trial Group

doi:10.1097/fjc.0b013e3181c87e37

Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease

Gorm B Jensen, Jørgen Hilden, Bodil Als-Nielsen, Morten Damgaard, Jørgen Fischer Hansen, Stig Hansen, Olav H Helø, Per Hildebrandt, Jens Kastrup, Hans Jørn Kolmos, Erik Kjøller, Inga Lind, Henrik Nielsen, Lars Petersen, Christian M Jespersen, Christian Gluud, CLARICOR Trial Group, Gorm B Jensen, Jørgen Hilden, Bodil Als-NielsenMorten Damgaard, Jørgen Fischer Hansen, Stig Hansen, Olav Holger Helø, Per Hildebrandt, Jens Kastrup, Hans Jørn Kolmos, Erik Kjøller, Inga Lind, Henrik Nielsen, Lars Petersen, Christian Jespersen, Christian Gluud, CLARICOR Trial Group

17 Citations (Scopus)

Abstract

In the CLARICOR trial, significantly increased cardiovascular (CV) and all-cause mortality in stable patients with coronary heart disease were observed after a short course of clarithromycin. We report on the impact of statin treatment at entry on the CV and all-cause mortality. The multicenter CLARICOR trial randomized patients to oral clarithromycin (500 mg daily; n = 2172) versus matching placebo (daily; n = 2201) for 2 weeks. Patients were followed through public databases. In the 41% patients on statin treatment at entry, no significant effect of clarithromycin was observed on CV (hazard ratio [HR], 0.68, 95% confidence interval [CI], 0.38-1.22; P = 0.20) or all-cause mortality (HR, 1.08; 95% CI, 0.71-1.65; P = 0.72) at 2.6-year follow up. In the patients not on statin treatment at entry, clarithromycin was associated with a significant increase in CV (HR, 1.90; 95% CI, 1.34-2.67; P = 0.0003; statin-clarithromycin interaction P = 0.0029) and all-cause mortality (HR, 1.33; 95% CI, 1.05-1.67; P = 0.016; statin-clarithromycin interaction P = 0.41). Multivariate analysis and 6-year follow up confirmed these results. Concomitant statin treatment in stable patients with coronary heart disease abrogated the observed increased CV mortality associated with 2 weeks of clarithromycin.

Original language	English
Journal	Journal of Cardiovascular Pharmacology
Volume	55
Issue number	2
Pages (from-to)	123-8
Number of pages	6
ISSN	0160-2446
DOIs	https://doi.org/10.1097/fjc.0b013e3181c87e37
Publication status	Published - 1 Feb 2010

Access to Document

10.1097/fjc.0b013e3181c87e37

Cite this

Jensen, G. B., Hilden, J., Als-Nielsen, B., Damgaard, M., Hansen, J. F., Hansen, S., Helø, O. H., Hildebrandt, P., Kastrup, J., Kolmos, H. J., Kjøller, E., Lind, I., Nielsen, H., Petersen, L., Jespersen, C. M., Gluud, C., CLARICOR Trial Group, Jensen, G. B., Hilden, J., ... CLARICOR Trial Group (2010). Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. Journal of Cardiovascular Pharmacology, 55(2), 123-8. https://doi.org/10.1097/fjc.0b013e3181c87e37

Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. / Jensen, Gorm B; Hilden, Jørgen; Als-Nielsen, Bodil et al.
In: Journal of Cardiovascular Pharmacology, Vol. 55, No. 2, 01.02.2010, p. 123-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Jensen, GB, Hilden, J, Als-Nielsen, B, Damgaard, M, Hansen, JF, Hansen, S, Helø, OH, Hildebrandt, P, Kastrup, J, Kolmos, HJ, Kjøller, E, Lind, I, Nielsen, H, Petersen, L, Jespersen, CM, Gluud, C, CLARICOR Trial Group, Jensen, GB, Hilden, J, Als-Nielsen, B, Damgaard, M, Hansen, JF, Hansen, S, Helø, OH, Hildebrandt, P, Kastrup, J, Kolmos, HJ, Kjøller, E, Lind, I, Nielsen, H, Petersen, L, Jespersen, C, Gluud, C & CLARICOR Trial Group 2010, 'Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease', Journal of Cardiovascular Pharmacology, vol. 55, no. 2, pp. 123-8. https://doi.org/10.1097/fjc.0b013e3181c87e37

@article{df734720829b11df928f000ea68e967b,

title = "Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease",

abstract = "In the CLARICOR trial, significantly increased cardiovascular (CV) and all-cause mortality in stable patients with coronary heart disease were observed after a short course of clarithromycin. We report on the impact of statin treatment at entry on the CV and all-cause mortality. The multicenter CLARICOR trial randomized patients to oral clarithromycin (500 mg daily; n = 2172) versus matching placebo (daily; n = 2201) for 2 weeks. Patients were followed through public databases. In the 41% patients on statin treatment at entry, no significant effect of clarithromycin was observed on CV (hazard ratio [HR], 0.68, 95% confidence interval [CI], 0.38-1.22; P = 0.20) or all-cause mortality (HR, 1.08; 95% CI, 0.71-1.65; P = 0.72) at 2.6-year follow up. In the patients not on statin treatment at entry, clarithromycin was associated with a significant increase in CV (HR, 1.90; 95% CI, 1.34-2.67; P = 0.0003; statin-clarithromycin interaction P = 0.0029) and all-cause mortality (HR, 1.33; 95% CI, 1.05-1.67; P = 0.016; statin-clarithromycin interaction P = 0.41). Multivariate analysis and 6-year follow up confirmed these results. Concomitant statin treatment in stable patients with coronary heart disease abrogated the observed increased CV mortality associated with 2 weeks of clarithromycin.",

author = "Jensen, {Gorm B} and J{\o}rgen Hilden and Bodil Als-Nielsen and Morten Damgaard and Hansen, {J{\o}rgen Fischer} and Stig Hansen and Hel{\o}, {Olav H} and Per Hildebrandt and Jens Kastrup and Kolmos, {Hans J{\o}rn} and Erik Kj{\o}ller and Inga Lind and Henrik Nielsen and Lars Petersen and Jespersen, {Christian M} and Christian Gluud and {CLARICOR Trial Group} and Jensen, {Gorm B} and J{\o}rgen Hilden and Bodil Als-Nielsen and Morten Damgaard and Hansen, {J{\o}rgen Fischer} and Stig Hansen and Hel{\o}, {Olav Holger} and Per Hildebrandt and Jens Kastrup and Kolmos, {Hans J{\o}rn} and Erik Kj{\o}ller and Inga Lind and Henrik Nielsen and Lars Petersen and Christian Jespersen and Christian Gluud and Nielsen, {Henrik Anker}",

year = "2010",

month = feb,

day = "1",

doi = "10.1097/fjc.0b013e3181c87e37",

language = "English",

volume = "55",

pages = "123--8",

journal = "Journal of Cardiovascular Pharmacology",

issn = "0160-2446",

publisher = "Lippincott Williams & Wilkins",

number = "2",

}

TY - JOUR

T1 - Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease

AU - Jensen, Gorm B

AU - Hilden, Jørgen

AU - Als-Nielsen, Bodil

AU - Damgaard, Morten

AU - Hansen, Jørgen Fischer

AU - Hansen, Stig

AU - Helø, Olav H

AU - Hildebrandt, Per

AU - Kastrup, Jens

AU - Kolmos, Hans Jørn

AU - Kjøller, Erik

AU - Lind, Inga

AU - Nielsen, Henrik

AU - Petersen, Lars

AU - Jespersen, Christian M

AU - Gluud, Christian

AU - CLARICOR Trial Group

AU - Jensen, Gorm B

AU - Hilden, Jørgen

AU - Als-Nielsen, Bodil

AU - Damgaard, Morten

AU - Hansen, Jørgen Fischer

AU - Hansen, Stig

AU - Helø, Olav Holger

AU - Hildebrandt, Per

AU - Kastrup, Jens

AU - Kolmos, Hans Jørn

AU - Kjøller, Erik

AU - Lind, Inga

AU - Nielsen, Henrik

AU - Petersen, Lars

AU - Jespersen, Christian

AU - Gluud, Christian

AU - CLARICOR Trial Group

PY - 2010/2/1

Y1 - 2010/2/1

N2 - In the CLARICOR trial, significantly increased cardiovascular (CV) and all-cause mortality in stable patients with coronary heart disease were observed after a short course of clarithromycin. We report on the impact of statin treatment at entry on the CV and all-cause mortality. The multicenter CLARICOR trial randomized patients to oral clarithromycin (500 mg daily; n = 2172) versus matching placebo (daily; n = 2201) for 2 weeks. Patients were followed through public databases. In the 41% patients on statin treatment at entry, no significant effect of clarithromycin was observed on CV (hazard ratio [HR], 0.68, 95% confidence interval [CI], 0.38-1.22; P = 0.20) or all-cause mortality (HR, 1.08; 95% CI, 0.71-1.65; P = 0.72) at 2.6-year follow up. In the patients not on statin treatment at entry, clarithromycin was associated with a significant increase in CV (HR, 1.90; 95% CI, 1.34-2.67; P = 0.0003; statin-clarithromycin interaction P = 0.0029) and all-cause mortality (HR, 1.33; 95% CI, 1.05-1.67; P = 0.016; statin-clarithromycin interaction P = 0.41). Multivariate analysis and 6-year follow up confirmed these results. Concomitant statin treatment in stable patients with coronary heart disease abrogated the observed increased CV mortality associated with 2 weeks of clarithromycin.

AB - In the CLARICOR trial, significantly increased cardiovascular (CV) and all-cause mortality in stable patients with coronary heart disease were observed after a short course of clarithromycin. We report on the impact of statin treatment at entry on the CV and all-cause mortality. The multicenter CLARICOR trial randomized patients to oral clarithromycin (500 mg daily; n = 2172) versus matching placebo (daily; n = 2201) for 2 weeks. Patients were followed through public databases. In the 41% patients on statin treatment at entry, no significant effect of clarithromycin was observed on CV (hazard ratio [HR], 0.68, 95% confidence interval [CI], 0.38-1.22; P = 0.20) or all-cause mortality (HR, 1.08; 95% CI, 0.71-1.65; P = 0.72) at 2.6-year follow up. In the patients not on statin treatment at entry, clarithromycin was associated with a significant increase in CV (HR, 1.90; 95% CI, 1.34-2.67; P = 0.0003; statin-clarithromycin interaction P = 0.0029) and all-cause mortality (HR, 1.33; 95% CI, 1.05-1.67; P = 0.016; statin-clarithromycin interaction P = 0.41). Multivariate analysis and 6-year follow up confirmed these results. Concomitant statin treatment in stable patients with coronary heart disease abrogated the observed increased CV mortality associated with 2 weeks of clarithromycin.

U2 - 10.1097/fjc.0b013e3181c87e37

DO - 10.1097/fjc.0b013e3181c87e37

M3 - Journal article

C2 - 19920766

SN - 0160-2446

VL - 55

SP - 123

EP - 128

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

IS - 2

ER -

Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease

Abstract

Access to Document

Fingerprint

Cite this